Loading…
Gyre Therapeutics, Inc. is projected to rise to $6.03 by 2027, a +5% move from its current price of $5.75. GYRE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $5.59 | $5.75 | $5.92 | +0.01% |
| Aug 3 | $5.52 | $5.75 | $5.99 | +0.03% |
| Aug 4 | $5.47 | $5.75 | $6.05 | +0.04% |
| Aug 5 | $5.43 | $5.75 | $6.09 | +0.06% |
| Aug 6 | $5.40 | $5.75 | $6.14 | +0.07% |
| Aug 7 | $5.36 | $5.76 | $6.18 | +0.09% |
| Aug 8 | $5.33 | $5.76 | $6.21 | +0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.33 | $5.76 | $6.21 | +0.10% |
| Week 2 | $5.17 | $5.76 | $6.42 | +0.21% |
| Week 3 | $5.06 | $5.77 | $6.58 | +0.31% |
| Week 4 | $4.96 | $5.77 | $6.72 | +0.41% |
| Week 5 | $4.88 | $5.78 | $6.85 | +0.52% |
| Week 6 | $4.80 | $5.79 | $6.97 | +0.62% |
| Week 7 | $4.74 | $5.79 | $7.08 | +0.72% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Gyre Therapeutics, Inc. is a pharmaceutical company that engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease.
Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics, Inc. (GYRE) is categorized in Healthcare and is currently trading with a price of $6.05 per share and a market cap of $674.51M. The company holds a rank of 2715 in market listings.
The current price and market position are tracked against a multi-year forecast that shows a path from neutral in the near term to bullish in the longer term. These dynamics are reflected in the price trajectory and the forecasted growth in value over time.
A major floor 21.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.9% away) — a key level to hold.
The nearest ceiling, 27.7% above — a clean break opens room to run.
A major ceiling 40.9% above — clearing it would confirm fresh momentum.
Key GYRE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GYRE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.86 | Sell | $5.83 | Sell |
| MA 10 | $5.92 | Sell | $5.95 | Sell |
| MA 20 | $6.27 | Sell | $6.11 | Sell |
| MA 50 | $6.18 | Sell | $6.35 | Sell |
| MA 100 | $6.78 | Sell | $6.70 | Sell |
| MA 200 | $7.31 | Sell | $7.24 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.57 | Neutral |
| Stoch RSI (14) | 23.32 | Neutral |
| CCI (20) | -92.09 | Neutral |
| Williams %R (14) | -88.04 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -12.35 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 11.96 | Buy |
| TRIX (15) | -0.23 | Sell |
| Awesome (5,34) | -0.41 | Sell |
| Ultimate (7,14,28) | 40.55 | Neutral |
| Momentum (10) | -0.30 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 5.72 | Buy |
| ADX (14) | 14.89 | Neutral |
| ATR (14) | 0.17 | Info |
The near-term technical picture shows bearish sentiment. RSI14 is 40, and the price trades below the SMA50 of $6.41 and below the SMA200 of $7.39. A defined support level sits at $5.82 and a resistance level at $7.34.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.56 | $5.75 | $7.51 | 0% | Neutral | |
| $4.78 | $6.03 | $8.04 | +5% | Neutral | |
| $5.03 | $6.53 | $9.06 | +14% | Neutral | |
| $5.16 | $6.86 | $9.82 | +19% | Neutral | |
| $5.84 | $7.94 | $11.65 | +38% | Bullish | |
| $6.63 | $9.21 | $13.82 | +60% | Bullish | |
| $7.04 | $9.94 | $15.23 | +73% | Bullish | |
| $7.24 | $10.41 | $16.24 | +81% | Bullish | |
| $6.79 | $9.93 | $15.74 | +73% | Bullish | |
| $7.02 | $10.42 | $16.78 | +81% | Bullish | |
| $9.84 | $15.70 | $26.96 | +173% | Bullish | |
| $14.75 | $26.66 | $50.25 | +364% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $5.56 | $5.75 | $7.12 | +0.00% |
| September 2026 | $5.06 | $6.00 | $7.32 | +4.37% |
| October 2026 | $4.88 | $5.83 | $7.19 | -2.89% |
| November 2026 | $4.84 | $5.81 | $7.23 | -0.37% |
| December 2026 | $4.96 | $5.99 | $7.51 | +3.12% |
Click any year to see its month-by-month GYRE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Gyre Therapeutics, Inc.'s 2026 outlook centres on $5.75, within a $5.56 to $7.51 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, GYRE could reach as high as $8.04, with a base case around $6.03 and support toward $4.78 — roughly +5% from $5.75. A consolidation phase looks the most probable path here.
Expect GYRE to range from $5.03 to $9.06 through 2028. The $6.53 average target implies a +14% move from current prices. That is up +8% on the projected 2027 average. Price action looks broadly range-bound.
The GYRE price prediction for 2029 points to an average of $6.86 (low $5.16, high $9.82) — a potential gain of +19% on today's $5.75. A consolidation phase looks the most probable path here.
In 2030, GYRE is projected to trade between $5.84 and $11.65, averaging $7.94 — a potential gain of +38% from today's $5.75. That is up +16% on the projected 2029 average. Momentum favours further upside here.
Gyre Therapeutics, Inc.'s 2031 outlook centres on $9.21, within a $6.63 to $13.82 range. That is up +16% on the projected 2030 average. That marks a +60% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, GYRE could reach as high as $15.23, with a base case around $9.94 and support toward $7.04 — roughly +73% from $5.75. Momentum favours further upside here.
Expect GYRE to range from $7.24 to $16.24 through 2033. The $10.41 average target implies a +81% move from current prices. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The GYRE price prediction for 2034 points to an average of $9.93 (low $6.79, high $15.74) — a potential gain of +73% on today's $5.75. Momentum favours further upside here.
In 2035, GYRE is projected to trade between $7.02 and $16.78, averaging $10.42 — a potential gain of +81% from today's $5.75. That is up +5% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Gyre Therapeutics, Inc.'s 2040 outlook centres on $15.70, within a $9.84 to $26.96 range. That is up +51% on the projected 2035 average. That marks a +173% change versus current levels. Momentum favours further upside here.
By 2050, GYRE could reach as high as $50.25, with a base case around $26.66 and support toward $14.75 — roughly +364% from $5.75. Buyers look set to stay in control over this stretch.
Investing $1,000 in GYRE today (≈ 173.913043 GYRE) could be worth
$4,637.33
+$3,637.33 (+364%) by 2050 · US Dollar
Based on the average projected GYRE price of $26.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GYREwould be worth at today's price.
$1,000 invested in GYRE on Jul 31, 2025 (≈ 141.843968 GYRE) would be worth
$815.6
-$184.4 (-18.4%) today · 0.82× · US Dollar
Based on a GYRE entry price of $7.05 vs. today's $5.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.94 | $968.01 | -3.2% |
| 1 month ago | $6.52 | $881.9 | -11.8% |
| 3 months ago | $7.8 | $737.18 | -26.3% |
| 6 months ago | $8.21 | $700.37 | -30.0% |
| 1 year ago | $7.05 | $815.6 | -18.4% |
| All time (5.0y) ago | $62.1 | $92.59 | -90.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GYRE forecast.
Our base-case forecast reaches $12.00 around 2040.
Implied market cap at $12.00: $1.34B
The multi-year forecast displays a shift from neutral to bullish over time. For 2030 the average forecast is $7.93 with a minimum of $5.70 and a maximum of $11.91, yielding a 31% return. The forecast continues to show bullish momentum through 2040 (avg $15.86, ROI 162.2%) and 2050 (avg $25.96, ROI 329%), with a max near $50.98.
Early years (2026-2029) show neutral sentiment, turning bullish from 2030 onward. These are estimates, not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
2030: avg $7.93, min $5.70, max $11.91, ROI 31%, sentiment BULLISH.
The forecasts show neutral sentiment in 2026–2029 and bullish sentiment from 2030 onward, with higher projected averages through 2030–2050 (e.g., avg $7.93 in 2030 and avg $25.96 in 2050). These are estimates and not guarantees.
Yes, the forecast lists a max of $50.98 in 2050 with an avg of $25.96 and ROI of 329%.
The 30-day range is $4.90 to $7.47. RSI14 is 40, SMA50 is $6.41, SMA200 is $7.39. Support is $5.82 and resistance is $7.34; annualized volatility is 60%.
Current price is $6.05 and market cap is $674.51M. The stock ranks 2715.
Gyre Therapeutics, Inc. Community Discussion
0Share your Gyre Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.